Looking for practical takes on upgraded andme? Here’s how we’re thinking about it this week.
We are upgrading 23andMe’s stock price:
- Increased adoption of direct-to-consumer (DTC) genetic testing: The market for DTC genetic testing is projected to grow in the coming years, which could benefit 23andMe.
- Expansion into new markets or partnerships: Entering new markets or forming strategic partnerships could boost revenue and investor confidence.
- Breakthroughs in gene editing or personalized medicine: Advancements in these areas could significantly impact 23andMe’s future potential.
- Artificial Manipulation of stock: We believe stock price is being artificially manipulated to make it more attractive to larger firms for a takeover
Our near term price target is $2.28
Quick questions
What should traders watch related to Upgraded 23andME to .28?
Focus on catalysts that move price this week — data prints, earnings, and liquidity — then check whether your setup still has a clear target and time window before you size up.
How does MoneyChoice help with upgraded andme?
MoneyChoice publishes timed ideas with price targets and a public accuracy trail. Start with Capital or browse live ideas — then apply your own risk rules.
Is this investment advice?
No. These posts are educational market commentary. Trading involves risk, and past model hit rates do not guarantee future results.